UNSPSC 51313210: Cycliramine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H19ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N61YTN00CK, chemically known as 4-(p-chloro-.alpha.-2-pyridylbenzylidene)-1-methylpiperidine but generally known as cycliramine, which bears US NIH Compound Identifier 5357113. The term cycliramine is an International Non-Proprietary Name or INN. European Medicines Agency schedules cycliramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06846MIG.

Most nations schedule cycliramine under HS 29333999 and SITC 51574. As of Q4 2014, CYCLIRAMINE remains the US FDA Preferred Term for this commodity. Cycliramine bears US NLM identifiers UMLS ID C2828319 and NCI Concept Code C87479. SMILES: CN1CCC(=C(C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CC1.C(=CC(=O)O)C(=O)O.

UNSPSC 51313210 Cycliramine is a Commodity code under which state and local governments procure pharmaceutical products, though the recent activity shows minimal direct solicitation for cycliramine itself and instead reflects broader procurement for naloxone, generic pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. The issuing bodies soliciting under related pharmaceutical categories span county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple state and local jurisdictions. The work being bought includes community health naloxone distribution systems, generic multi-source pharmaceutical supply agreements, and exploratory direct-to-manufacturer prescription fulfillment models designed to improve cost management and operational efficiency in state and local healthcare delivery.

Recent activity shows geographic concentration in Florida and the Upper Midwest, with solicitations from Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which serves participating state and local facilities including Oregon. Representative opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026, and MMCAP's RFP S1070000015802, posted January 20, 2026, with a March 26, 2026 response deadline, establishing multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers with contract effectiveness on July 1, 2026. The Texas Health and Human Services Commission also issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs, signaling state interest in alternative pharmaceutical procurement models outside traditional pharmacy benefit manager relationships.